Up to now, the second-generation BRAF inhibitors vemurafenib (PLX4032) and dabrafenib (GSK2118436) were approved by the United States Food and Drug Administration (FDA) for the treatment of patients with metastatic melanomas harboring BRAF V600 mutations (Karoulia et al., 2017). Here, BRAF is linked to melanoma.